Topic: Bristol-Myers Squibb Company
Data from AVERROES Trial of Investigational Drug Apixaban Will Be Presented During a Hot Line Session at Upcoming European Society of Cardiology Meeting. Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from the Phase 3 AVERROES clinical ...
BMY) today announced revisions to the U.S. prescribing information for PLAVIX (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite. ...
Phase III Data Published in The Lancet also Demonstrate Comparable Rates of Bleeding with Apixaban Versus Enoxaparin. In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an investigational oral anticoagulant discovered by Bristol-Myers Squibb being ...
Bristol-Myers Squibb Co. and Pfizer Inc. on Thursday said their blood thinner apixaban was more effective than Sanofi-Aventis' Lovenox in a late stage clinical trial.. The study compared the drugs' ability to reduce blood clots in the legs or lungs, also called ...
Bristol-Myers licenses rights from Toyko firms for experimental drug for common heart disorderBristol-Myers Squibb Co. and two Japanese firms said Wednesday night they will collaborate to develop and sell an experimental drug meant to correct a dangerous abnormal heart rhythm called atrial ...
BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing regimens of Plavix(R) (clopidogrel bisulfate) and aspirin on cardiovascular outcomes and bleeding complications in ...
PFE) announced today the results of a Phase 2 dose-ranging study (APPRAISE-1) involving the investigational compound apixaban in patients with acute coronary syndrome (ACS, commonly known as heart attack or severe chest pain). The six-month APPRAISE-1 study was not powered to demonstrate ...
In addition, Bristol-Myers Squibb and Pfizer reported that an early evaluation of results from a Phase III study of apixaban for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement indicates that the primary endpoint of this study was ...
The FDA posted a black-box warning added to Definity, a Bristol-Myers Squibb drug used in conjunction with ultrasound imaging to diagnose heart problems, Dow Jones Newswires reports.. The Health Blog reported on Sunday that the agency has been investigating reports of deaths ...
First-in-Class Compound Designed to Improve Clinical Outcomes During Treatment of a Heart Attack. Bristol-Myers Squibb will fund all future development, including the Phase 2b clinical trial to be conducted by KAI. In addition, at KAI's option, Bristol-Myers Squibb will purchase $10 million ...
Photo Gallery
From Around the Web
Video Gallery
-
Company Profile: Bristol-Myers Squibb Company (NYS...
The company's blockbuster cardiovascular line-up includes heart disease drug ...2010-04-21 -
Bristol-Myers Bids $5.2B For ImClone ...
Bristol-Myers Squibb Company has offered to buy ImClone Systems Inc ...2008-08-01 -
Analyst Insight: Morgan Stanley Downgraded Bristol...
Morgan Stanley analysts are downgrading Bristol-Myers Squibb (NYSE:BMY) to ...2010-10-04
